REFERENCES
1. Ravishankar V. March of cardiac surgery through the decades. Med J Armed Forces India 2014;70:3-4.
2. Konstantinov IE. At the cutting edge of the impossible: a tribute to Vladimir P. Demikhov. Tex Heart Inst J 2009;36:453-8.
3. Lower RR, Stofer RC, Hurley EJ, Dong E Jr, Cohn RB, Shumway NE. Successful homotransplantation of the canine heart after anoxic preservation for seven hours. Am J Surg 1962;104:302-6.
4. Dong E Jr, Hurley EJ, Lower RR, Shumway NE. Performance of the heart two years after autotransplantation. Surgery 1964;56:270-4.
5. Shumway NE, Lower RR. Special problems in transplantation of the heart. Ann N Y Acad Sci 1964;120:773-7.
6. Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 1967;41:1271-4.
7. Lansman SL, Ergin MA, Griepp RB. The history of heart and heart-lung transplantation. Cardiovasc Clin 1990;20:3-19.
8. Stehlik J, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD, Kirk R, Dobbels F, Rahmel AO, Hertz MI. The registry of the international society for heart and lung transplantation: twenty-seventh official adult heart transplant report--2010. J Heart Lung Transplant 2010;29:1089-103.
9. Lietz K, Miller LW. Improved survival of patients with end-stage heart failure listed for heart transplantation: analysis of organ procurement and transplantation network/U.S. United Network of Organ Sharing data, 1990 to 2005. J Am Coll Cardiol 2007;50:1282-90.
10. Abuanzeh R, Hashmi F, Dimarakis I, Khasati N, Machaal A, Yonan N, Venkateswaran RV. Early donor management increases the retrieval rate of hearts for transplantation in marginal donors. Eur J Cardiothorac Surg 2015;47:72-7; discussion 77.
11. Ringer S. A further contribution regarding the influence of the different constituents of the blood on the contraction of the heart. J Physiol 1883;4:29-42.
12. Tyers GF, Todd GJ, Niebauer IM, Manley NJ, Waldhausen JA. The mechanism of myocardial damage following potassium citrate (Melrose) cardioplegia. Surgery 1975;78:45-53.
13. Maathuis MH, Leuvenink HG, Ploeg RJ. Perspectives in organ preservation. Transplantation 2007;83:1289-98.
14. tHart NA, Leuvenink HGD, Ploeg RJ. New solutions in organ preservation. Available from: http://www.sciencedirect.com/science/article/pii/S0955470X02800027. [Last accessed on 20 Oct 2017].
15. Shumway NE, Lower RR. Topical cardiac hypothermia for extended periods of anoxic arrest. Surg Forum 1960;10:563-6.
16. Blaisdell FW, Cooley DA. The mechanism of paraplegia after temporary thoracic aortic occlusion and its relationship to spinal fluid pressure. Surgery 1962;51:351-5.
17. Kay EB, Head LR, Nogueira C. Direct coronary artery perfusion for aortic valve surgery; report of technique. J Am Med Assoc 1958;168:1767-8.
18. Senning A. Ventricular fibrillation during hypothermia, used as a method to facilitate intracardiac operations. Acta Chir Scand 1955;109:303-9.
19. Bretschneider HJ, Hübner G, Knoll D, Lohr B, Nordbeck H, Spieckermann PG. Myocardial resistance and tolerance to ischemia: physiological and biochemical basis. J Cardiovasc Surg (Torino) 1975;16:241-60.
20. Hearse DJ, Stewart DA, Braimbridge MV. Cellular protection during myocardial ischemia: the development and characterization of a procedure for the induction of reversible ischaemic arrest. Circulation 1976;54:193-202.
21. Buckberg GD. Recent progress in myocardial protection during cardiac operations. Cardiovasc Clin 1987;17:291-319.
22. Hearse DJ, Humphrey SM, Nayler WG, Slade A, Border D. Ultrastructural damage associated with reoxygenation of the anoxic myocardium. J Mol Cell Cardiol 1975;7:315-24.
23. Chambers DJ, Fallouh HB. Cardioplegia and cardiac surgery: pharmacological arrest and cardioprotection during global ischemia and reperfusion. Pharmacol Ther 2010;127:41-52.
24. Reichenspurner H, Russ C, Uberfuhr P, Nollert G, Schlüter A, Reichart B, Klövekorn WP, Schüler S, Hetzer R, Brett W. Myocardial preservation using HTK solution for heart transplantation. A multicenter study. Eur J Cardiothorac Surg 1993;7:414-9.
25. Sung SY, Lin CY, Song JY, Tsai YT, Kao CH, Lee CY, Lin YC, Hsu PS, Tsai CS. Myocardial protection in donor heart preservation: a comparison between Bretschneider's histidine-tryptophan-ketoglutarate solution and cold blood cardioplegia. Transplant Proc 2014;46:1077-81.
26. Minami K, Omoto T, Böthig D, Tenderich G, Wlost S, Schütt U, Körfer R. Creatine kinase and troponin after myocardial preservation using HTK solution (Custoidol) for clinical heart transplantation. J Heart Lung Transplant 2003;22:192-4.
27. Larsen M, Webb G, Kennington S, Kelleher N, Sheppard J, Kuo J, Unsworth-White J. Mannitol in cardioplegia as an oxygen free radical scavenger measured by malondialdehyde. Perfusion 2002;17:51-5.
29. Chambers DJ, Sakai A, Braimbridge MV, Kosker S, Manzanera G, Kind PR, Jupp RA, Smith LD, Slavin B. Clinical validation of St. Thomas' hospital cardioplegic solution No. 2 (Plegisol). Eur J Cardiothorac Surg 1989;3:346-52.
30. Luciani GB, Faggian G, Montalbano G, Casali G, Forni A, Chiominto B, Mazzucco A. Blood versus crystalloid cardioplegia for myocardial protection of donor hearts during transplantation: a prospective, randomized clinical trial. J Thorac Cardiovasc Surg 1999;118:787-95.
31. Luciani GB, Forni A, Rigatelli G, Chiominto B, Cardaioli P, Mazzucco A, Faggian G. Myocardial protection in heart transplantation using blood cardioplegia: 12-year outcome of a prospective randomized trial. J Heart Lung Transplant 2011;30:29-36.
32. Collins GM, Hartley LC, Clunie GJ. Kidney preservation for transportation. Experimental analysis of optimal perfusate composition. Br J Surg 1972;59:187-9.
33. Andrews PM, Bates SB. Improving Euro-Collins flushing solution's ability to protect kidneys from normothermic ischemia. Miner Electrolyte Metab 1985;11:309-13.
34. Hendry PJ, Labow RS, Keon WJ. A comparison of intracellular solutions for donor heart preservation. J Thorac Cardiovasc Surg 1993;105:667-73.
36. Ploeg RJ, Goossens D, McAnulty JF, Southard JH, Belzer FO. Successful 72-hour cold storage of dog kidneys with UW solution. Transplantation 1988;46:191-6.
37. Todo S, Nery J, Yanaga K, Podesta L, Gordon RD, Starzl TE. Extended preservation of human liver grafts with UW solution. JAMA 1989;261:711-4.
38. Jamieson NV, Sundberg R, Lindell S, Claesson K, Moen J, Vreugdenhil PK, Wight DG, Southard JH, Belzer FO. Preservation of the canine liver for 24-48 hours using simple cold storage with UW solution. Transplantation 1988;46:517-22.
39. Kozlova I, Khalid Y, Roomans GM. Preservation of mouse liver tissue during cold storage in experimental solutions assessed by x-ray microanalysis. Liver Transpl 2003;9:268-78.
40. Vreugdenhil PK, Belzer FO, Southard JH. Effect of cold storage on tissue and cellular glutathione. Cryobiology 1991;28:143-9.
41. Biguzas M, Jablonski P, Howden BO, Thomas AC, Walls K, Scott DF, Marshall VC. Evaluation of UW solution in rat kidney preservation. II. The effect of pharmacological additives. Transplantation 1990;49:1051-5.
42. Kur F, Beiras-Fernandez A, Meiser B, Uberfuhr P, Reichart B. Clinical heart transplantation with extended preservation time (> 5 hours): experience with University of Wisconsin solution. Transplant Proc 2009;41:2247-9.
43. Jeevanandam V, Barr ML, Auteri JS, Sanchez JA, Fong J, Schenkel FA, Marboe CC, Michler RE, Smith CR, Rose EA. University of Wisconsin solution versus crystalloid cardioplegia for human donor heart preservation. A randomized blinded prospective clinical trial. J Thorac Cardiovasc Surg 1992;103:194-8; discussion 198-9.
44. Mankad P, Slavik Z, Yacoub M. Endothelial dysfunction caused by University of Wisconsin preservation solution in the rat heart. The importance of temperature. J Thorac Cardiovasc Surg 1992;104:1618-24.
45. Saitoh Y, Hashimoto M, Ku K, Kin S, Nosaka S, Masumura S, Nakayama K. Heart preservation in HTK solution: role of coronary vasculature in recovery of cardiac function. Ann Thorac Surg 2000;69:107-12.
46. De Santo LS, Amarelli C, Romano G, Della Corte A, Maiello C, Giannolo B, Marra C, De Feo M, Scardone M, Cotrufo M. High-risk heart grafts: effective preservation with Celsior solution. Heart Vessels 2006;21:89-94.
47. Careaga G, Salazar D, Téllez S, Sánchez O, Borrayo G, Argüero R. Clinical impact of histidine-ketoglutarate-tryptophan (HTK) cardioplegic solution on the perioperative period in open heart surgery patients. Arch Med Res 2001;32:296-9.
48. Lee KC, Chang CY, Chuang YC, Sue SH, Yang HS, Weng CF, Lee YT, Huang WS, Chen IC, Wei J. Combined St. Thomas and histidine-tryptophan-ketoglutarat solutions for myocardial preservation in heart transplantation patients. Transplant Proc 2012;44:886-9.
49. Careaga G, Salazar D, Téllez S, Sánchez O, Borrayo G, Argüero R. Clinical impact of histidine-ketoglutarate-tryptophan (HTK) cardioplegic solution on the perioperative period in open heart surgery patients. Arch Med Res 2001;32:296-9.
50. Vega JD, Ochsner JL, Jeevanandam V, McGiffin DC, McCurry KR, Mentzer RM Jr, Stringham JC, Pierson RN 3rd, Frazier OH, Menkis AH, Staples ED, Modry DL, Emery RW, Piccione W Jr, Carrier M, Hendry PJ, Aziz S, Furukawa S, Pham SM. A multicenter, randomized, controlled trial of Celsior for flush and hypothermic storage of cardiac allografts. Ann Thorac Surg 2001;71:1442-7.
51. Wieselthaler GM, Chevtchik O, Konetschny R, Moidl R, Mallinger R, Mares P, Griessmacher A, Grimm M, Wolner E, Laufer G. Improved graft function using a new myocardial preservation solution: Celsior. Preliminary data from a randomized prospective study. Transplant Proc 1999;31:2067-8.
52. Cannata A, Botta L, Colombo T, Russo CF, Taglieri C, Bruschi G, Merlanti B, Frigerio M, Martinelli L. Does the cardioplegic solution have an effect on early outcomes following heart transplantation? Eur J Cardiothorac Surg 2012;41:e48-52; discussion e52-3.
53. George TJ, Arnaoutakis GJ, Beaty CA, Shah AS, Conte JV, Halushka MK. A novel method of measuring cardiac preservation injury demonstrates University of Wisconsin solution is associated with less ischaemic necrosis than Celsior in early cardiac allograft biopsy specimens. J Heart Lung Transplant 2012;31:410-8.
54. George TJ, Arnaoutakis GJ, Baumgartner WA, Shah AS, Conte JV. Organ storage with University of Wisconsin solution is associated with improved outcomes after orthotopic heart transplantation. J Heart Lung Transplant 2011;30:1033-43.
55. Kofler S, Bigdeli AK, Kaczmarek I, Kellerer D, Müller T, Schmoeckel M, Steinbeck G, Uberfuhr P, Reichart B, Meiser B. Long-term outcomes after 1000 heart transplantations in six different eras of innovation in a single center. Transpl Int 2009;22:1140-50.
56. Garlicki M, Kołcz J, Rudziński P, Kapelak B, Sadowski J, Wójcik S, Pietrzyk E, Frasik W, Drukała J, Dziatkowiak A. Myocardial protection for transplantation. Transplant Proc 1999;31:2079-83.
57. Lee S, Huang CS, Kawamura T, Shigemura N, Billiar TR, Nakao A, Toyoda Y. Histidine-tryptophan-ketoglutarate or celsior: which is more suitable for cold preservation for cardiac grafts from older donors? Ann Thorac Surg 2011;91:755-63.
58. Ackemann J, Gross W, Mory M, Schaefer M, Gebhard MM. Celsior versus custodiol: early postischemic recovery after cardioplegia and ischemia at 5 degrees C. Ann Thorac Surg 2002;74:522-9.
59. Lurati Buse GA, Koller MT, Grapow M, Bolliger D, Seeberger M, Filipovic M. The prognostic value of troponin release after adult cardiac surgery - a meta-analysis. Eur J Cardiothorac Surg 2010;37:399-406.
60. De Santo LS, Torella M, Romano G, Maiello C, Buonocore M, Bancone C, Della Corte A, Galdieri N, Nappi G, Amarelli C. Perioperative myocardial injury after adult heart transplant: determinants and prognostic value. PLoS One 2015;10:e0120813.
61. Gross GJ, Kersten JR JR, Warltier DC. Mechanisms of postischemic contractile dysfunction. Ann Thorac Surg 1999;68:1898-904.
62. Dengler TJ, Gleissner CA, Klingenberg R, Sack FU, Schnabel PA, Katus HA. Biomarkers after heart transplantation: nongenomic. Heart Fail Clin 2007;3:69-81.
63. Masuda M, Morita S, Tomita H, Kurisu K, Nishida T, Tominaga R, Yasui H. Off-pump CABG attenuates myocardial enzyme leakage but not postoperative brain natriuretic peptide secretion. Ann Thorac Cardiovasc Surg 2002;8:139-44.
64. Hajjar L, Galas F, Grande S, Campos M, Silva R, Marques A, Leao W, Auler Jr J. Plasma brain natriuretic peptide and cardiac troponin I concentrations after adult cardiac surgery: association with cardiovascular death, postoperative cardiac, renal and pulmonary dysfunction. Available from: https://ccforum.biomedcentral.com/track/pdf/10.1186/cc6665. [Last accessed on 20 Oct 2017].
65. McIlroy DR, Wallace S, Roubos N. Brain natriuretic peptide (BNP) as a biomarker of myocardial ischemia-reperfusion injury in cardiac transplantation. J Cardiothorac Vasc Anesth 2010;24:939-45.
66. Cavarretta E, Frati G. MicroRNAs in coronary heart disease: ready to enter the clinical arena? Biomed Res Int 2016;2016:2150763.
67. Wang E, Nie Y, Zhao Q, Wang W, Huang J, Liao Z, Zhang H, Hu S, Zheng Z. Circulating miRNAs reflect early myocardial injury and recovery after heart transplantation. J Cardiothorac Surg 2013;8:165.
68. Russo MJ, Chen JM, Sorabella RA, Martens TP, Garrido M, Davies RR, George I, Cheema FH, Mosca RS, Mital S, Ascheim DD, Argenziano M, Stewart AS, Oz MC, Naka Y. The effect of ischaemic time on survival after heart transplantation varies by donor age: an analysis of the United Network for organ sharing database. J Thorac Cardiovasc Surg 2007;133:554-9.
69. Goldsmith KA, Demiris N, Gooi JH, Sharples LD, Jenkins DP, Dhital KK, Tsui SS. Life-years gained by reducing donor heart ischaemic times. Transplantation 2009;87:243-8.
70. Hassanein WH, Zellos L, Tyrrell TA, Healey NA, Crittenden MD, Birjiniuk V, Khuri SF. Continuous perfusion of donor hearts in the beating state extends preservation time and improves recovery of function. J Thorac Cardiovasc Surg 1998;116:821-30.
71. Messer S, Ardehali A, Tsui S. Normothermic donor heart perfusion: current clinical experience and the future. Transpl Int 2015;28:634-42.
72. Tenderich G, El-Banayosy A, Rosengard B, Tsui S, Wallwork J, Hetzer R, Koerfer R, Hassanein W. 10: Prospective multi-center European trial to evaluate the safety and performance of the Organ Care System for heart transplants (PROTECT). Available from: http://www.jhltonline.org/article/S1053-2498(06)00824-2/fulltext. [Last accessed on 20 Oct 2017].
73. McCurry K, Jeevanandam V, Mihaljevic T, Couper G, Elanwar M, Saleh H, Ardehali A. 294: Prospective Multi-center safety and effectiveness evaluation of the Organ Care System device for cardiac use (PROCEED). Available from: http://www.jhltonline.org/article/S1053-2498(07)01142-4/abstract. [Last accessed on 20 Oct 2017].
74. Hamed A, Tsui S, Huber J, Lin R, Poggio EC, Ardehali A. 19: Serum lactate is a highly sensitive and specific predictor of post cardiac transplant outcomes using the Organ Care System. J Heart Lung Transplant 2009;28:S71.
75. Ardehali A, Esmailian F, Deng M, Soltesz E, Hsich E, Naka Y, Mancini D, Camacho M, Zucker M, Leprince P, Padera R, Kobashigawa J; PROCEED II trial investigators. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised non-inferiority trial. Lancet 2015;385:2577-84.
76. Daemen JW, Kootstra G, Wijnen RM, Yin M, Heineman E. Nonheart-beating donors: the Maastricht experience. Clin Transpl 1994:303-16.
77. Iyer A, Gao L, Doyle A, Rao P, Cropper JR, Soto C, Dinale A, Kumarasinghe G, Jabbour A, Hicks M, Jansz PC, Feneley MP, Harvey RP, Graham RM, Dhital KK, MacDonald PS. Normothermic ex vivo perfusion provides superior organ preservation and enables viability assessment of hearts from DCD donors. Am J Transplant 2015;15:371-80.
78. Dhital KK, Iyer A, Connellan M, Chew HC, Gao L, Doyle A, Hicks M, Kumarasinghe G, Soto C, Dinale A, Cartwright B, Nair P, Granger E, Jansz P, Jabbour A, Kotlyar E, Keogh A, Hayward C, Graham R, Spratt P, Macdonald P. Adult heart transplantation with distant procurement and ex-vivo preservation of donor hearts after circulatory death: a case series. Lancet 2015;385:2585-91.
79. Boucek MM, Mashburn C, Dunn SM, Frizell R, Edwards L, Pietra B, Campbell D; Denver Children's Pediatric Heart Transplant Team. Pediatric heart transplantation after declaration of cardiocirculatory death. N Engl J Med 2008;359:709-14.
80. Walsh F. Europe's first non-beating heart transplant. Available from: http://www.bbc.com/news/health-32056350. [Last accessed on 20 Oct 2017].
81. Truog RD, Miller FG, Halpern SD. The dead-donor rule and the future of organ donation. N Engl J Med 2013;369:1287-9.
82. Ullah S, Zabala L, Watkins B, Schmitz ML. Cardiac organ donor management. Perfusion 2006;21:93-8.
83. Cuisinier A, Maufrais C, Payen JF, Nottin S, Walther G, Bouzat P. Myocardial function at the early phase of traumatic brain injury: a prospective controlled study. Scand J Trauma Resusc Emerg Med 2016;24:129.
84. Novitzky D, Rhodin J, Cooper DK, Ye Y, Min KW, DeBault L. Ultrastructure changes associated with brain death in the human donor heart. Transpl Int 1997;10:24-32.
85. Kilic A, Emani S, Sai-Sudhakar CB, Higgins RS, Whitson BA. Donor selection in heart transplantation. J Thorac Dis 2014;6:1097-104.
86. Lee H, Cho YH, Sung K, Yang JH, Chung CR, Jeon K, Suh GY. The use of extracorporeal circulation in suspected brain dead organ donors with cardiopulmonary collapse. J Korean Med Sci 2015;30:1911-4.
87. Cooper LB, Milano CA, Williams M, Swafford W, Croezen D, Van Bakel AB, Rogers JG, Patel CB. Thyroid hormone use during cardiac transplant organ procurement. Clin Transplant 2016;30:1578-83.
88. Novitzky D, Cooper DK, Rosendale JD, Kauffman HM. Hormonal therapy of the brain-dead organ donor: experimental and clinical studies. Transplantation 2006;82:1396-401.
89. Novitzky D, Cooper DK, Wicomb W. Hormonal therapy to the brain-dead potential organ donor: the misnomer of the "Papworth cocktail". Transplantation 2008;86:1479.
90. Wheeldon DR, Potter CD, Oduro A, Wallwork J, Large SR. Transforming the "unacceptable" donor: outcomes from the adoption of a standardized donor management technique. J Heart Lung Transplant 1995;14:734-42.
91. Wojda TR, Stawicki SP, Yandle KP, Bleil M, Axelband J, Wilde-Onia R, Thomas PG, Cipolla J, Hoff WS, Shultz J. Keys to successful organ procurement: an experience-based review of clinical practices at a high-performing health-care organization. Int J Crit Illn Inj Sci 2017;7:91-100.
92. Hahnenkamp K, Böhler K, Wolters H, Wiebe K, Schneider D, Schmidt HH. Organ-protective intensive care in organ donors. Dtsch Arztebl Int 2016;113:552-8.
93. Nicolas-Robin A, Barouk JD, Amour J, Coriat P, Riou B, Langeron O. Hydrocortisone supplementation enhances hemodynamic stability in brain-dead patients. Anesthesiology 2010;112:1204-10.
94. Novitzky D, Cooper DK, Muchmore JS, Zuhdi N. Pituitary function in brain-dead patients. Transplantation 1989;48:1078-9.
95. Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995;152:838-60.
96. Clemente G, Tuttolomondo A, Colomba D, Pecoraro R, Renda C, Della Corte V, Maida C, Simonetta I, Pinto A. When sepsis affects the heart: a case report and literature review. World J Clin Cases 2015;3:743-50.
97. McLean KM, Duffy JY, Pandalai PK, Lyons JM, Bulcao CF, Wagner CJ, Akhter SA, Pearl JM. Glucocorticoids alter the balance between pro- and anti-inflammatory mediators in the myocardium in a porcine model of brain death. J Heart Lung Transplant 2007;26:78-84.
99. Pandit RA, Zirpe KG, Gurav SK, Kulkarni AP, Karnath S, Govil D, Abhram B, Mehta Y, Gupta A, Hegde A, Patil V, Bhatacharya P, Dixit S, Samavedan S, Todi S. Management of potential organ donor: Indian society of critical care medicine: position statement. Indian J Crit Care Med 2017;21:303-16.
100. Pinsard M, Ragot S, Mertes PM, Bleichner JP, Zitouni S, Cook F, Pierrot M, Dube L, Menguy E, Lefèvre LM, Escaravage L, Dequin PF, Vignon P, Pichon N. Interest of low-dose hydrocortisone therapy during brain-dead organ donor resuscitation: the CORTICOME study. Crit Care 2014;18:R158.
101. Dimopoulou I, Tsagarakis S, Anthi A, Milou E, Ilias I, Stavrakaki K, Charalambidis C, Tzanela M, Orfanos S, Mandragos K, Thalassinos N, Roussos C. High prevalence of decreased cortisol reserve in brain-dead potential organ donors. Crit Care Med 2003;31:1113-7.
102. Dhar R, Cotton C, Coleman J, Brockmeier D, Kappel D, Marklin G, Wright R. Comparison of high- and low-dose corticosteroid regimens for organ donor management. J Crit Care 2013;28:111. e1-7
103. Novitzky D, Cooper DK, Chaffin JS, Greer AE, DeBault LE, Zuhdi N. Improved cardiac allograft function following triiodothyronine therapy to both donor and recipient. Transplantation 1990;49:311-6.
104. Chen YF, Kobayashi S, Chen J, Redetzke RA, Said S, Liang Q, Gerdes AM. Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats. J Mol Cell Cardiol 2008;44:180-7.
105. Jeevanandam V, Todd B, Regillo T, Hellman S, Eldridge C, McClurken J. Reversal of donor myocardial dysfunction by triiodothyronine replacement therapy. J Heart Lung Transplant 1994;13:681-7; discussion 685-7.
106. Novitzky D, Mi Z, Sun Q, Collins JF, Cooper DK. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis. Transplantation 2014;98:1119-27.
107. Macdonald PS, Aneman A, Bhonagiri D, Jones D, O'Callaghan G, Silvester W, Watson A, Dobb G. A systematic review and meta-analysis of clinical trials of thyroid hormone administration to brain dead potential organ donors. Crit Care Med 2012;40:1635-44.
108. Venkateswaran RV, Steeds RP, Quinn DW, Nightingale P, Wilson IC, Mascaro JG, Thompson RD, Townend JN, Bonser RS. The haemodynamic effects of adjunctive hormone therapy in potential heart donors: a prospective randomized double-blind factorially designed controlled trial. Eur Heart J 2009;30:1771-80.
109. Novitzky D, Wicomb WN, Cooper DK, Tjaalgard MA. Improved cardiac function following hormonal therapy in brain dead pigs: relevance to organ donation. Cryobiology 1987;24:1-10.
110. Votapka TV, Canvasser DA, Pennington DG, Koga M, Swartz MT. Effect of triiodothyronine on graft function in a model of heart transplantation. Ann Thorac Surg 1996;62:78-82.
111. Hing AJ, Hicks M, Garlick SR, Gao L, Kesteven SH, Faddy SC, Wilson MK, Feneley MP, Macdonald PS. The effects of hormone resuscitation on cardiac function and hemodynamics in a porcine brain-dead organ donor model. Am J Transplant 2007;7:809-17.
112. Zimmerman EA, Nilaver G, Hou-Yu A, Silverman AJ. Vasopressinergic and oxytocinergic pathways in the central nervous system. Fed Proc 1984;43:91-6.
113. Yoshioka T, Sugimoto H, Uenishi M, Sakamoto T, Sadamitsu D, Sakano T, Sugimoto T. Prolonged hemodynamic maintenance by the combined administration of vasopressin and epinephrine in brain death: a clinical study. Neurosurgery 1986;18:565-7.
114. Blaine EM, Tallman RD Jr, Frolicher D, Jordan MA, Bluth LL, Howie MB. Vasopressin supplementation in a porcine model of brain-dead potential organ donors. Transplantation 1984;38:459-64.
115. Rostron AJ, Avlonitis VS, Cork DM, Grenade DS, Kirby JA, Dark JH. Hemodynamic resuscitation with arginine vasopressin reduces lung injury after brain death in the transplant donor. Transplantation 2008;85:597-606.
116. Chen JM, Cullinane S, Spanier TB, Artrip JH, John R, Edwards NM, Oz MC, Landry DW. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors. Circulation 1999;100:II244-6.
117. Pennefather SH, Bullock RE, Mantle D, Dark JH. Use of low dose arginine vasopressin to support brain-dead organ donors. Transplantation 1995;59:58-62.
118. Kinoshita Y, Yahata K, Yoshioka T, Onishi S, Sugimoto T. Long-term renal preservation after brain death maintained with vasopressin and epinephrine. Transpl Int 1990;3:15-8.
119. Papadopoulos G, Sintou E, Siminelakis S, Koletsis E, Baikoussis NG, Apostolakis E. Perioperative infusion of low- dose of vasopressin for prevention and management of vasodilatory vasoplegic syndrome in patients undergoing coronary artery bypass grafting-A double-blind randomized study. J Cardiothorac Surg 2010;5:17.
120. Calva E, Mújica A, Nú-ez R, Aoki K, Bisteni A, Sodi-Pallares D. Mitochondrial biochemical changes and glucose-KCl-insulin solution in cardiac infarct. Am J Physiol 1966;211:71-6.
121. Opie LH, Bruyneel K, Owen P. Effects of glucose, insulin and potassium infusion on tissue metabolic changes within first hour of myocardial infarction in the baboon. Circulation 1975;52:49-57.
122. Sodi-pallares D, Testelli MR, Fishleder BL, Bisteni A, Medrano GA, Friedland C, De Micheli A. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol 1962;9:166-81.
123. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997;96:1152-6.
124. Sun SC, Appleyard R, Masetti P, Byrne JG, Laurence RG, Marsh JD, Cohn LH. Improved recovery of heart transplants by combined use of oxygen-derived free radical scavengers and energy enhancement. J Thorac Cardiovasc Surg 1992;104:830-7.
125. Pilati CF, Bosso FJ, Maron MB. Factors involved in left ventricular dysfunction after massive sympathetic activation. Am J Physiol 1992;263:H784-91.
126. Szabo G, Buhmann V, Bahrle S, Vahl CF, Hagl S. Brain death impairs coronary endothelial function. Transplantation 2002;73:1846-8.
127. Nicolas-Robin A, Amour J, Ibanez-Esteve C, Coriat P, Riou B, Langeron O. Effect of glucose-insulin-potassium in severe acute heart failure after brain death. Crit Care Med 2008;36:2740-5.
128. Heusch G, Schulz R, Rahimtoola SH. Myocardial hibernation: a delicate balance. Am J Physiol Heart Circ Physiol 2005;288:H984-99.
129. Stanley AW Jr, Moraski RE, Russell RO, Rogers WJ, Mantle JA, Kreisberg RA, McDaniel HG, Rackley CE. Effects of glucose-insulin-potassium on myocardial substrate availability and utilization in stable coronary artery disease. Studies on myocardial carbohydrate, lipid and oxygen arterial-coronary sinus differences in patients with coronary artery disease. Am J Cardiol 1975;36:929-37.
130. Taegtmeyer H, Goodwin GW, Doenst T, Frazier OH. Substrate metabolism as a determinant for postischemic functional recovery of the heart. Am J Cardiol 1997;80:A3-10.
131. Cottin Y, Lhuillier I, Gilson L, Zeller M, Bonnet C, Toulouse C, Louis P, Rochette L, Girard C, Wolf JE. Glucose insulin potassium infusion improves systolic function in patients with chronic ischaemic cardiomyopathy. Eur J Heart Fail 2002;4:181-4.
132. Khoury VK, Haluska B, Prins J, Marwick TH. Effects of glucose-insulin-potassium infusion on chronic ischaemic left ventricular dysfunction. Heart 2003;89:61-5.
133. Demircan S, Yazici M, Diraman E, Demircan G, Kilicaslan F, Durna K, Acar Z, Eren Z. The effect of glucose-insulin-potassium treatment on myocardial oxidative stress in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Coron Artery Dis 2008;19:99-104.
134. Kalay N, Ozdogru I, Gul A, Yucel Y, Cetinkaya Y, Inanc MT, Dogan A, Kaya MG, Eryol NK. Effects of intermittent and long-term glucose-insulin-potassium infusion in patients with systolic heart failure. Exp Clin Cardiol 2008;13:85-8.
135. Klein LJ, van Campen CM, Sieswerda GT, Kamp O, Visser FC. Effects of high-dose insulin infusion on left ventricular function in normal subjects. Neth Heart J 2010;18:183-9.
136. Meybohm P, Bein B, Brosteanu O, Cremer J, Gruenewald M, Stoppe C, Coburn M, Schaelte G, Böning A, Niemann B, Roesner J, Kletzin F, Strouhal U, Reyher C, Laufenberg-Feldmann R, Ferner M, Brandes IF, Bauer M, Stehr SN, Kortgen A, Wittmann M, Baumgarten G, Meyer-Treschan T, Kienbaum P, Heringlake M, Schön J, Sander M, Treskatsch S, Smul T, Wolwender E, Schilling T, Fuernau G, Hasenclever D, Zacharowski K; RIPHeart Study Collaborators. A multicenter trial of remote ischaemic preconditioning for heart surgery. N Engl J Med 2015;373:1397-407.
137. Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson S, Xenou M, Clayton T, Yellon DM; ERICCA Trial Investigators. Remote ischaemic preconditioning and outcomes of cardiac surgery. N Engl J Med 2015;373:1408-17.
138. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischaemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893-9.
139. Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhäuser M, Peters J, Jakob H, Heusch G. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 2013;382:597-604.
140. Hong DM, Lee EH, Kim HJ, Min JJ, Chin JH, Choi DK, Bahk JH, Sim JY, Choi IC, Jeon Y. Does remote ischaemic preconditioning with postconditioning improve clinical outcomes of patients undergoing cardiac surgery? Remote ischaemic preconditioning with postconditioning outcome trial. Eur Heart J 2014;35:176-83.
141. Sachdeva J, Dai W, Gerczuk PZ, Kloner RA. Combined remote perconditioning and postconditioning failed to attenuate infarct size and contractile dysfunction in a rat model of coronary artery occlusion. J Cardiovasc Pharmacol Ther 2014;19:567-73.
142. Eitel I, Stiermaier T, Rommel KP, Fuernau G, Sandri M, Mangner N, Linke A, Erbs S, Lurz P, Boudriot E, Mende M, Desch S, Schuler G, Thiele H. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: the randomized lipsia conditioning trial. Eur Heart J 2015;36:3049-57.
143. Pichot S, Mewton N, Bejan-Angoulvant T, Roubille F, Rioufol G, Giraud C, Boussaha I, Lairez O, Elbaz M, Piot C, Angoulvant D, Ovize M. Influence of cardiovascular risk factors on infarct size and interaction with mechanical ischaemic postconditioning in ST-elevation myocardial infarction. Open Heart 2015;2:e000175.
144. Moscarelli M, Angelini GD, Suleiman S, Fiorentino F, Punjabi PP. Remote ischaemic preconditioning: is it a flag on the field? Perfusion 2015;30:438-47.
145. Kottenberg E, Musiolik J, Thielmann M, Jakob H, Peters J, Heusch G. Interference of propofol with signal transducer and activator of transcription 5 activation and cardioprotection by remote ischaemic preconditioning during coronary artery bypass grafting. J Thorac Cardiovasc Surg 2014;147:376-82.
146. Kleinbongard P, Neuhäuser M, Thielmann M, Kottenberg E, Peters J, Jakob H, Heusch G. Confounders of cardioprotection by remote ischaemic preconditioning in patients undergoing coronary artery bypass grafting. Cardiology 2016;133:128-33.
147. Hausenloy DJ, Boston-Griffiths EA, Yellon DM. Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol 2012;165:1235-45.
148. Hausenloy DJ, Kunst G, Boston-Griffiths E, Kolvekar S, Chaubey S, John L, Desai J, Yellon D. The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial. Heart 2014;100:544-9.
149. Iyer A, Gao L, Doyle A, Rao P, Jayewardene D, Wan B, Kumarasinghe G, Jabbour A, Hicks M, Jansz PC, Feneley MP, Harvey RP, Graham RM, Dhital KK, Macdonald PS. Increasing the tolerance of DCD hearts to warm ischemia by pharmacological postconditioning. Am J Transplant 2014;14:1744-52.
150. Watson AJ, Gao L, Sun L, Tsun J, Jabbour A, Ru Qiu M, Jansz PC, Hicks M, Macdonald PS. Enhanced preservation of the rat heart after prolonged hypothermic ischemia with erythropoietin-supplemented Celsior solution. J Heart Lung Transplant 2013;32:633-40.
151. Trahanas JM, Witer LJ, Alghanem F, Bryner BS, Iyengar A, Hirschl JR, Hoenerhoff MJ, Potkay JA, Bartlett RH, Rojas-Pena A, Owens GE, Bocks ML. Achieving 12 hour normothermic ex situ heart perfusion: an experience of 40 porcine hearts. ASAIO J 2016;62:470-6.
152. Hing AJ, Watson A, Hicks M, Gao L, Faddy SC, McMahon AC, Kesteven SH, Wilson MK, Jansz P, Feneley MP, Macdonald PS. Combining cariporide with glyceryl trinitrate optimizes cardiac preservation during porcine heart transplantation. Am J Transplant 2009;9:2048-56.
